clinical trial · NCT07105124
Safety and Tolerability, and PK of Sibeprenlimab in Chinese Healthy Subject
Otsuka Beijing Research Institute·phase1·completed·n = 24
Healthy Subjects (HS)Sibeprenlimab
brief summary
A Trial to Assess the Pharmacokinetics, Safety and Tolerability, and Pharmacodynamics, of Sibeprenlimab Solution Administered Subcutaneously in Chinese Healthy Subjects
started
Oct 18, 2022
primary completion
Feb 15, 2023
completion
Feb 15, 2023
last updated
Aug 5, 2025
official title
A Randomized, Open-label, Phase 1 Trial to Assess the Pharmacokinetics, Safety and Tolerability, and Pharmacodynamics of Sibeprenlimab Solution Administered Subcutaneously in Chinese Healthy Subjects
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol